Comparative Pharmacology
Head-to-head clinical analysis: HISPRIL versus POLARAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISPRIL versus POLARAMINE.
HISPRIL vs POLARAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISPRIL (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and afterload.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
10 mg orally once daily, increased to 20 mg once daily after 2-4 weeks if needed.
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
None Documented
None Documented
The terminal elimination half-life of HISPRIL is approximately 12-15 hours in patients with normal renal function, supporting twice-daily dosing. In moderate to severe renal impairment (CrCl <30 mL/min), half-life is prolonged up to 30-40 hours, necessitating dose interval adjustment.
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
HISPRIL is predominantly excreted renally, with approximately 60-70% of an administered dose recovered unchanged in urine over 48 hours. Hepatic metabolism accounts for <10% of elimination, and fecal excretion contributes <5%.
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Category C
Category C
Antihistamine
Antihistamine